Purified PPT1 (C-His) final product on SDS-PAGE under non-reducing (P-) and reducing (P+) conditions. The purity of PPT1 expressed in CHO cells appears to be greater than 95%.
Cat #
Size
Price
Quantity
601201
25 ug
$145
601202
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
CHO
Target Name
Palmitoyl-protein thioesterase 1
Species
Human
accession number
P50897.1
Sources
human PPT1 (Asp28-Gly306) with C-terminus His tag was expressed in CHO cells
Molecular Weight
This protein has a predicted molecular weight of 32.6 kDa. Under DTT-reducing conditions, the protein migrates at approximately 35-40 kDa on SDS-PAGE.
Affinity Tag
C-His
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
Palmitoyl-protein thioesterase 1 (PPT1) is a lysosomal enzyme that hydrolyzes thioester-linked palmitate from S-palmitoylated proteins, facilitating their degradation during lysosomal processing. PPT1 is a glycosylated monomer with a catalytic triad and fatty acid-binding groove, and plays a key role in the autophagy-lysosome pathway. Mutations in the PPT1 gene cause infantile neuronal ceroid lipofuscinosis (INCL), a severe lysosomal storage disorder characterized by accumulation of lipid-modified proteins, leading to neurodegeneration, mental retardation, and early death. In addition to INCL, impaired PPT1 function has been associated with Huntington’s disease, Alzheimer’s disease, schizophrenia, and cancer, due to its influence on synaptic function and protein trafficking.
Purified PPT1 (C-His) final product on SDS-PAGE under non-reducing (P-) and reducing (P+) conditions. The purity of PPT1 expressed in CHO cells appears to be greater than 95%.
